BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 30958538)

  • 1. Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients.
    Fontana L; Perlin DS; Zhao Y; Noble BN; Lewis JS; Strasfeld L; Hakki M
    Clin Infect Dis; 2020 Feb; 70(5):723-730. PubMed ID: 30958538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy & hematopoietic stem cell transplant patients.
    Khatri AM; Natori Y; Anderson A; Jabr R; Shah SA; Natori A; Chandhok NS; Komanduri K; Morris MI; Camargo JF; Raja M
    Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14162. PubMed ID: 37794708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Stern A; Su Y; Lee YJ; Seo S; Shaffer B; Tamari R; Gyurkocza B; Barker J; Bogler Y; Giralt S; Perales MA; Papanicolaou GA
    Biol Blood Marrow Transplant; 2020 Jun; 26(6):1195-1202. PubMed ID: 32088367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study).
    Monforte A; Los-Arcos I; Martín-Gómez MT; Campany-Herrero D; Sacanell J; Berastegui C; Márquez-Algaba E; Sempere A; Nuvials X; Deu M; Castells L; Moreso F; Bravo C; Gavaldà J; Len O
    Microbiol Spectr; 2022 Feb; 10(1):e0178421. PubMed ID: 35171022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
    Bogler Y; Stern A; Su Y; Lee YJ; Seo SK; Shaffer B; Perales MA; Papanicolaou GA; Neofytos D
    Med Mycol; 2021 Oct; 59(10):970-979. PubMed ID: 34036319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients.
    Samanta P; Clancy CJ; Marini RV; Rivosecchi RM; McCreary EK; Shields RK; Falcione BA; Viehman A; Sacha L; Kwak EJ; Silveira FP; Sanchez PG; Morrell M; Clarke L; Nguyen MH
    Clin Infect Dis; 2021 Aug; 73(3):416-426. PubMed ID: 32463873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study.
    Auberger J; Lass-Flörl C; Aigner M; Clausen J; Gastl G; Nachbaur D
    J Antimicrob Chemother; 2012 Sep; 67(9):2268-73. PubMed ID: 22653819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Case Series and Literature Review of Isavuconazole Use in Pediatric Patients with Hemato-oncologic Diseases and Hematopoietic Stem Cell Transplantation.
    Decembrino N; Perruccio K; Zecca M; Colombini A; Calore E; Muggeo P; Soncini E; Comelli A; Molinaro M; Goffredo BM; De Gregori S; Giardini I; Scudeller L; Cesaro S
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.
    Rausch CR; DiPippo AJ; Jiang Y; DiNardo CD; Kadia T; Maiti A; Montalban-Bravo G; Ravandi F; Kontoyiannis DP
    Clin Infect Dis; 2022 Oct; 75(9):1503-1510. PubMed ID: 35325094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isavuconazole for the prophylaxis and treatment of invasive fungal disease: A single-center experience.
    Vu CA; Rana MM; Jacobs SE; Saunders-Hao P
    Transpl Infect Dis; 2021 Apr; 23(2):e13469. PubMed ID: 32946658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.
    Wu X; Venkataramanan R; Rivosecchi RM; Tang C; Marini RV; Shields RK; Clancy CJ; Nguyen MH
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of Toxicity With Long-term Isavuconazole Use in Patients With Hematologic Malignancy.
    DiPippo AJ; Kontoyiannis DP
    Clin Infect Dis; 2019 Oct; 69(9):1624-1627. PubMed ID: 30861066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis.
    Biehl LM; Vehreschild JJ; Liss B; Franke B; Markiefka B; Persigehl T; Bücker V; Wisplinghoff H; Scheid C; Cornely OA; Vehreschild MJ
    J Antimicrob Chemother; 2016 Sep; 71(9):2634-41. PubMed ID: 27317443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Isavuconazonium Sulfate in Pediatrics Patients With Hematologic Malignancies and Hematopoietic Cell Transplantation With Invasive Fungal Infections: A Real World Experience.
    Ross JA; Karras NA; Tegtmeier B; Yamada C; Chen J; Sun W; Pawlowska A; Rosenthal J; Zaia J; Dadwal S
    J Pediatr Hematol Oncol; 2020 May; 42(4):261-265. PubMed ID: 32218096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breakthrough invasive fungal infection in patients with myeloid malignancy receiving posaconazole tablet prophylaxis: Clinical features, risk factors, and posaconazole profiles.
    Hong JY; Kang CI; Yang J; Ko JH; Huh K; Cho SY; Chung DR; Jung CW; Peck KR
    Med Mycol; 2023 Apr; 61(5):. PubMed ID: 37120735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal prophylaxis in haematology patients: the role of voriconazole.
    Hicheri Y; Cook G; Cordonnier C
    Clin Microbiol Infect; 2012 Apr; 18 Suppl 2():1-15. PubMed ID: 22409648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
    Chou LS; Lewis RE; Ippoliti C; Champlin RE; Kontoyiannis DP
    Pharmacotherapy; 2007 Dec; 27(12):1644-50. PubMed ID: 18041885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refining the therapeutic range of posaconazole and isavuconazole for efficient therapeutic drug monitoring using a bioassay approach.
    Willeman T; Tonini J; Garnaud C; Bailly S; Gandia P; Stanke-Labesque F; Maubon D; Gautier-Veyret E
    Fundam Clin Pharmacol; 2020 Apr; 34(2):279-287. PubMed ID: 31505058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful Treatment of Invasive Fungal Infection Due to Highly Resistant Aspergillus calidoustus in an Allogeneic Hematopoietic Cell Transplant Recipient.
    Mendoza MA; Anderson A; Morris MI; Lekakis L; Simkins J; Prado CE; Martinez OV; Komanduri KV; Camargo JF
    Mycopathologia; 2020 Apr; 185(2):399-403. PubMed ID: 31925638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.
    Tverdek FP; Heo ST; Aitken SL; Granwehr B; Kontoyiannis DP
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.